MitoQ is a dietary supplement that carries a coenzyme Q10-like antioxidant into cells' energy-producing structures, sold for healthy aging. Its most consistent finding in people is better artery-lining function, mainly in older or less fit people whose arteries were already underperforming. Other uses show small, mixed or no benefit. Short-term safety at usual doses looks reassuring. Much evidence was partly manufacturer-funded; MitoQ remains plausible but unproven for blood vessel aging. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Brachial flow-mediated dilation (FMD) | 6% or higher | Expected to change: main benefit marker |
| Carotid-femoral pulse wave velocity (PWV) | Below 7.60 m/s | Expected to change in those with elevated stiffness |
| Blood pressure | No target given | Baseline safety screen; affects PWV |
| Oxidized LDL (oxLDL) | No established target; track change from own baseline | Expected to change |
| Serum creatinine | Men 0.7–1.3 mg/dL; women 0.6–1.1 mg/dL | Safety check: rising values prompt stopping |
| Alanine aminotransferase (ALT) | 7–56 U/L | Safety check: new elevation prompts stopping |
| Estimated glomerular filtration rate (eGFR) | No target given | Kidney function estimate; paired with creatinine |
| Aspartate aminotransferase (AST) | No target given | Liver enzyme; paired with ALT |
| Standard lipid panel | No target given | Paired with oxLDL |
Cadence: Baseline, repeat at 6–12 weeks, then every 6–12 months; kidney and liver tests at 8–12 weeks in kidney or liver disease